{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:04:31Z","timestamp":1792652671269,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.yrtph.2024.105570","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T01:38:02Z","timestamp":1706319482000},"page":"105570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?"],"prefix":"10.1016","volume":"148","author":[{"given":"Greet B.A.","family":"Teuns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Tessari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2024.105570_bib1","series-title":"Australian Public Assessment Report for Suvorexant. Proprietary Product Name: Belsomra","year":"2015"},{"key":"10.1016\/j.yrtph.2024.105570_bib2","unstructured":"AVMA Guidelines on Euthanasia. Current Version."},{"key":"10.1016\/j.yrtph.2024.105570_bib3","series-title":"Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes","year":"1991"},{"key":"10.1016\/j.yrtph.2024.105570_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.yrtph.2017.03.006","article-title":"Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant","volume":"86","author":"Born","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105570_bib6","series-title":"Guideline on the Non-clinical Investigation of the Dependence Potential of Medicinal Products","year":"2006"},{"key":"10.1016\/j.yrtph.2024.105570_bib5","series-title":"Drug abuse prevention and control Act of 1970, commonly known as the controlled substance Act (CSA), 1970","year":"1970"},{"key":"10.1016\/j.yrtph.2024.105570_bib7","unstructured":"European Convention (ETS No. 123) for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.."},{"key":"10.1016\/j.yrtph.2024.105570_bib8","series-title":"Assessment of Abuse Potential of Drugs. Final Guidance","year":"2017"},{"key":"10.1016\/j.yrtph.2024.105570_bib9","series-title":"Non-compartmental Analysis. Pharmacokinetic and Pharmacodynamic Data Analysis. Concepts & Applications","first-page":"141","author":"Gabrielsson","year":"2000"},{"key":"10.1016\/j.yrtph.2024.105570_bib10","article-title":"Guidance of nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Current step 4-version","volume":"11","year":"2009","journal-title":"June"},{"key":"10.1016\/j.yrtph.2024.105570_bib11","article-title":"Safety, tolerability, and pharmacokinetics of suvorexant: a randomized rising-dose trial in healthy men","author":"Lai Yee","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.yrtph.2024.105570_bib12","article-title":"The controlled substances Act (CSA): a legal overview for the 116th congress","author":"Lampe","year":"2019","journal-title":"Joanna R. Lampe: Legislative Attorney"},{"issue":"2","key":"10.1016\/j.yrtph.2024.105570_bib13","first-page":"205","article-title":"Animal experimentation in Italy. Legislation and the authorization of research protocols","volume":"40","author":"Panzini","year":"2004","journal-title":"Ann. Ist. Super Sanita"},{"key":"10.1016\/j.yrtph.2024.105570_bib14","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.2147\/DDDT.S73224","article-title":"Profile of suvorexant in the management of insomnia","volume":"9","author":"Sutton","year":"2015","journal-title":"Drug Des Devel Ther. 2015"},{"key":"10.1016\/j.yrtph.2024.105570_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.vascn.2014.02.002","article-title":"Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models","volume":"70","author":"Teuns","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2024.105570_bib16","series-title":"Drug Scheduling. 10 July","year":"2018"},{"key":"10.1016\/j.yrtph.2024.105570_bib17","series-title":"Review NDA Original Application Number 204569Orig1s000","year":"2014"},{"issue":"30","key":"10.1016\/j.yrtph.2024.105570_bib18","first-page":"8639","article-title":"Proposed rules: docket No. DEA\u2013381 schedules of controlled substances: placement of suvorexant into schedule IV","volume":"79","year":"2014"},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2024.105570_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant-A novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J. Neurogenet."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:35:56Z","timestamp":1759494956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"alternative-id":["S0273230024000114"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105570","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105570"}}